Department Viroscience, Erasmus MC, University Medical Center Rotterdam, The Netherlands.
Department Viroscience, Erasmus MC, University Medical Center Rotterdam, The Netherlands.
Curr Opin Virol. 2021 Oct;50:8-16. doi: 10.1016/j.coviro.2021.06.007. Epub 2021 Jun 29.
SARS-CoV-2 emerged in China as a zoonotic virus in December 2019. The virus proved to be human-to-human transmissible and its global spread resulted in the ongoing COVID-19 pandemic, associated with high morbidity and mortality. Vaccines were developed at an unprecedented speed and proved to be efficacious in preventing disease, but it remains to be determined if vaccines are able to interrupt transmission. Moreover, virus variants of concern continue to emerge that appear more transmissible and/or less sensitive to virus-specific immune responses. Here, we briefly review the role of animal models in assessing prophylactic and therapeutic options to interrupt SARS-CoV-2 transmission.
SARS-CoV-2 作为一种人畜共患病病毒于 2019 年 12 月在中国出现。该病毒被证明可以在人与人之间传播，其在全球范围内的传播导致了持续的 COVID-19 大流行，发病率和死亡率都很高。疫苗的开发速度前所未有，被证明在预防疾病方面是有效的，但仍有待确定疫苗是否能够阻断传播。此外，持续出现令人关注的病毒变异株，这些变异株似乎更具传染性和/或对病毒特异性免疫反应的敏感性更低。在这里，我们简要回顾了动物模型在评估预防和治疗方案以阻断 SARS-CoV-2 传播方面的作用。
